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Abstract The human P2Y! purinoceptor has been expressed in 
Jurkat cells and the effects of HPLC purified nucleotides on 
calcium movements were measured. The most potent agonist was 
2-methylthio-ADP followed by ADP. ATP, Sp-ATPctS and ß,^ 
methylene-ATP were competitive antagonists. Suramin and 
PPADS inhibited the effects of ADP. This pharmacological 
profile is the same as that of the so-called P2T purinoceptor 
responsible for platelet aggregation, which has not yet been 
identified. Using PCR we found the P2Y] receptor to be present 
in blood platelets and megakaryoblastic cell lines. These data 
suggest that the P2Yx receptor may be the elusive P2T receptor. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Extracellular nucleotides exert their diverse biological ef-
fects [1] through P2 receptors, as opposed to PI purinergic 
receptors which are responsive to nucleosides [2]. On the basis 
of differential vascular responses to ATP and its analogues, P2 
receptors were first subclassified as P2X and P2Y receptors 
[3]. Since the first molecular characterization of a P2Y recep-
tor in 1993 [4], there has been an explosion in the cloning of 
purinoceptors. These are now divided into two broad families 
[5]: P2X ionotropic receptors (P2Xi-P2X7) which are ATP 
ligand-gated ion channel receptors, and P2Y metabotropic 
seven transmembrane domain receptors coupled to G-proteins 
(P2Y]-P2Y8) which are responsive to adenine or uridine nu-
cleotides. Other P2 receptors have been described mainly from 
pharmacological data. This is the case of the platelet P2T 
receptor, responsible for platelet aggregation, where all at-
tempts at cloning have to date been unsuccessful. The expres-
sion of P2T seems to be restricted to platelets and megakar-
yoblastic cell lines [6-9], ADP being its natural agonist and 
ATP a competitive antagonist [10,11]. Platelet activation by 
ADP involves not only mobilization of intracellular calcium 
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Abbreviations: ADP, adenosine 5'-diphosphate; Sp-ADPaS, adeno-
sine 5'-0-(l-thiodiphosphate) (Sp isomer); ADPßS, adenosine 5'-0-(2-
thiodiphosphate) ; ATP, adenosine 5'-triphosphate; 2MeSATP, 2-
methylthio-adenosine 5'-triphosphate; 2MeSADP, 2-methylthio-ade-
nosine 5'-diphosphate; 2C1ATP, 2-chloro-adenosine 5'-triphosphate; 
2C1ADP, 2-chloro-adenosine 5'-diphosphate; aßMeATP, a,ß-methyl-
ene-ATP; ßyMeATP, ß,y-methylene-ATP; Sp-ATPaS, adenosine-5'-
O-(l-thiotriphosphate); UTP, uridine 5'-triphosphate; PPADS, pyr-
idoxalphosphate-6-azophenyl-2',4'-disulfonic acid 
stores but also a rapid influx of calcium [12], presumably 
through P2X receptors [13]. ADP also inhibits stimulated ad-
enylate cyclase but this is not the cause of platelet aggregation 
[14]. On account of its coupling to a Gi protein of the ai2 
subtype [15], the P2T receptor is thought to belong to the P2Y 
metabotropic receptor family. 
The first metabotropic receptor to be molecularly identified 
was the chick P2Yi receptor [4], after which successive species 
homologues were cloned from turkey [16], rat and mouse [17], 
bovine [18] and human tissues [19]. Recently, a pharmacolog-
ical characterization of the human P2Yi receptor has been 
reported, using measurements of inositol phosphate produc-
tion in response to various ATP and ADP analogues [20,21]. 
Pharmacological characterization of nucleotide receptor sub-
types is nevertheless hampered by the absence of selective 
agonists and antagonists and by the presence of synthesis 
by-products in commercial nucleotide sources. Furthermore, 
ATP and ADP analogues are more or less metabolically un-
stable and may be degraded by the ectonucleotidases present 
on cells. In the present paper, we report a new pharmacolog-
ical characterization of the human P2Yi receptor using puri-
fied nucleotides. This receptor was found to be not a nucleo-
tide triphosphate receptor but a nucleotide diphosphate 
receptor and was shown to strikingly resemble the platelet 
P2T receptor with triphosphate nucleotides antagonizing the 
diphosphate nucleotides effects. Moreover, this P2Yi receptor 
was found to be expressed both in platelets and in megakar-
yoblastic cell lines. 
2. Materials and methods 
2.1. Cell culture 
Jurkat E6.1 cells (ECACC No. 88042803, Cerdic, France) and 
megakaryoblastic cell lines Dami, MEG-01, CHRF-288, K562 and 
HEL [22] were grown in RPMI-1640 medium supplemented with 
10% (v/v) heat-inactivated fetal calf serum, 2 mM glutamine, 100 U/ 
ml penicillin and 0.1 mg/ml streptomycin (media and supplements 
from Gibco-BRL, Life Sciences, Cergy-Pontoise, France). Cultures 
were kept at 37°C in a humidified atmosphere containing 5% CO2 
and cells were subcultured every 3 days so as to maintain a density of 
approximately 5X105 cells/ml. 
2.2. cDNA cloning, sequencing and heterologous expression 
A 2300 bp cDNA fragment was isolated from a human placental 
cDNA library (kind gift from Prof. P. Chambon) using a previously 
described procedure [19]. The clone was rescued in pMosElox (Amer-
sham Life Science, UK) and sequenced in both directions using the 
Sanger dideoxy chain termination method (Sequenase kit version 2.0, 
Amersham). An expression vector containing the coding sequence was 
constructed by insertion of the BamHl-EcoKY P2Y fragment into the 
BamH\ and Sma\ sites of pCDNA3 (Invitrogen, Abingdon, UK). 
Expression vectors with and without the P2Yi coding sequence were 
linearized with Pvu\ and electroporated into Jurkat E6.1 cells (Cell-
ject, Eurogentec, Seraing, Belgium) using 250 V, 1500 uF, and infinite 
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resistance. Transfected cells were selected with geneticin (1 mg/ml; 
Boehringer, Mannheim, Germany) 48 h after electroporation. Cells 
were subsequently cloned by limiting dilution and about 20 clones 
were screened for expression of the P2 receptor. 
2.3. Measurement of [Cai+]\ 
Cells were washed in basal salt solution (BSS) (25 mM HEPES, pH 
7.3. 125 mM NaCl, 5 mM KC1, 1 mM MgCl2, 5 mM glucose, 0.1% 
human essentially fatty acid free serum albumin (Sigma, Saint Quen-
tin-Fallavier, France)) supplemented with 2 mM CaCl2. After centrif-
ugation (100 Xg, 5 min), the cells were resuspended in BSS without 
calcium at a concentration of 15 X106 cells/ml and loaded with 5 |J,M 
fura-2/acetoxymethyl ester (fura-2/AM) at 37°C for 30 min in the 
dark. The cells were then pelleted and suspended at a density of 
1 X 106 cells/ml in BSS containing calcium. Intracellular concentration 
of calcium ([Ca2+]0 was measured in a PTI Deltascan spectrofluorim-
eter (Photon Technology International Inc., Princetown, NJ) using 
340 and 380 nm alternative excitation and 510 nm detection wave-
lengths. Similar [Ca2+]i responses could be detected with or without 
pretreatment of the cells with 2 U/ml of the ATP diphosphohydrolase 
apyrase (EC 3.6.1.5). 
2.4. Poly(A)+ RNA isolation, cDNA synthesis and polymerase chain 
reaction (PCR) amplification 
Human platelet concentrates (approximately 106 platelets/ul) were 
obtained from healthy donors. In order to eliminate white blood cells 
and the majority of erythrocytes, two or three successive centrifuga-
tions were performed in a Sorvall RC-3 centrifuge (570Xg for 10 s, 
without brake), the absence of white blood cells in platelet suspen-
sions being confirmed by counting cells with a hemacytometer (Sys-
mex K-1000, TOA Medical Electronics, Japan). Cell cultures in the 
exponential growth phase and human platelets were pelleted and total 
RNA was recovered using RNA NOW solution (Biogentex, Ozyme, 
Montigny-le Bretonneux, France). Poly(A)+ RNA was obtained by 
oligo(dT)-cellulose chromatography (QuickPrep Micro mRNA Purifi-
cation Kit, Pharmacia Biotech, Uppsala, Sweden) while cDNA was 
synthesized using a T-primed First Strand cDNA synthesizing kit 
(Pharmacia Biotech). The following oligonucleotides were employed 
to amplify the entire human P2Yi coding sequence: sense HP2YA (5'-
CTCGGAGCCGCCGCCTAAGTCGAGG-3') and antisense HP2YB 
(5'-CCTACCATATTACAACAGAGAGGTGT-3'). PCR reactions 
were carried out in a thermal cycler (GeneAmp PCR system 2400, 
Perkin Elmer, Roissy, France) using 35 cycles of 94°C for 30 s, 57°C 
for 45 s and 72°C for 45 s. Absence of exogenous or genomic DNA 
contamination was checked by performing experiments with no tem-
plate or RNA as template instead of cDNA. The 1198 bp PCR prod-
ucts were purified and sequenced as described. 
2.5. Materials 
ADP, Sp-ATPaS, ßyMeATP and UTP nucleotides were obtained 
from Boehringer (Mannheim, Germany), while ATP and aßMeATP 
were purchased from Sigma (Saint Quentin-Fallavier, France) and 
2MeSATP, 2C1ATP, 2MeSADP and PPADS from Research Bio-
chemical Incorporation (Natick, MA, USA). Fura-2/AM and suramin 
were obtained from Calbiochem (Meudon, France). All nucleotides 
were checked for purity by high performance liquid chromatography 
(HPLC) analysis. When necessary, nucleotides were purified by ion 
exchange chromatography on a Partisil 10 it SAX column (Inter-
chrom, Interchim, Monlucon, France) eluted with a linear gradient 
of 0-500 mM triethyl ammonium bicarbonate, pH 8.4, or with 50-800 
mM ammonium phosphate buffer, pH 3.8. Both buffers were previ-
ously checked for absence of effects on calcium measurements. 
3. Results 
Previously, we described the isolation of a human P2Yi 
receptor from a placental cDNA library [19]. Using exactly 
the same procedure, we have now isolated another 2.3 kb 
clone containing the same coding sequence with one excep-
tion : the presence of an additional 3 bp leading to an addi-
tional serine residue in transmembrane domain 3, between 
residues 137 and 138. The pCDNA3 vector alone and a vector 
containing the coding sequence of the serine-containing hu-
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Fig. 1. Effects of nucleotides on [Ca2+]j in fura-2-loaded Jurkat cells 
stably expressing the human P2Yi receptor. Increases in the ratio of 
fluorescence emission using 340 and 380 nm excitation wavelengths 
are expressed as a percentage of the maximal response obtained 
with 2MeSADP (IO -4 M), in response to various concentrations of 
nucleotides, using non-purified nucleotides (A) and HPLC-purified 
nucleotides (B). Inset, HPLC profiles of Sp-ATPaS (1) containing 
8% Sp-ADPaS (2) before (A) and after (B) purification. Curves 
each represent the results of five independent experiments and bars 
show the S.E.M. 
man placental P2Yi receptor were stably transfected into Jur-
kat E6.1 cells, a human cell line which is not naturally respon-
sive to nucleotides [18]. Geneticin-resistant cells were cloned 
and screened for ATP-induced increases in [Ca2+]j. Three in 
20 clones were found to express a functional serine-containing 
P2Yi receptor and the cellular clone which gave the best re-
sponse to ATP was chosen for further determination of the 
pharmacological profile. 
In order to characterize the pharmacology of the trans-
fected P2Y! receptor, increases in [Ca2+]; in response to var-
ious nucleotide analogues were measured and concentration-
response curves were generated (Fig. 1A). In a first approach, 
2MeSADP, 2MeSATP, 2C1ATP and ADP were found to be 
full agonists of the P2Yi receptor, producing a rapid rise in 
[Ca2+]i which peaked within 5 s and subsequently returned to 
basal levels in less than 3 min. 2C1ATP, 2MeSATP and 2Me-
SADP were the most potent agonists (EC50 = 40 ± 4 nM, 
45 ±13 nM and 49 ±10 nM respectively), being four times 
more potent than ADP (EC50 = 204±64 nM). Sp-ATPocS 
and ATP were partial agonists (EC50 — 380 ± 20 nM and 
11 ±7 uM respectively), while aßMeATP, ßyMeATP, UTP 
and adenosine were without agonistic effect. In a medium 
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Fig. 2. Effects of triphosphate nucleotides and P2 receptor antago-
nists on ADP-induced [Ca2+]j increase. Points are the mean of three 
determinations and bars show the S.E.M. A: Dose-dependent in-
creases in [Ca2+]i induced by ADP alone (o) or in the presence of 
ATP (100 uM) (•). B: Effects of aßMeATP (1 mM), ßyMeATP (1 
mM), Sp-ATPaS (10 uM), suramin (100 uM) and PPADS (10 nM) 
on the 1 (xM ADP-induced [Ca2+]; increase. Control experiment: 
ADP (1 uM) alone. 
containing no calcium (0.3 mM EGTA), 2MeSADP still eli-
cited a transient increase in [Ca2+]i, but with diminished am-
plitude indicating that the 2MeSADP-induced [Ca2+]j rise was 
due both to mobilization of calcium from internal stores and 
to entry of external calcium (data not shown). 
As already mentioned, commercial nucleotide powders are 
often contaminated by degradation products which can be the 
cause of misleading results. In order to exclude a possible 
contamination, and because of the observation that true an-
tagonists of ADP-induced platelet aggregation had agonistic 
activities on platelets, we then systematically purified all nu-
cleotides by HPLC immediately before use. In these condi-
tions, we observed no further agonistic effect of ATP. Sp-
ATPaS, a poorly hydrolyzable ATP analogue, contained 6-
10% Sp-ADPaS; once purified, 10 uM Sp-ATPaS was inef-
fective, whereas the contaminating Sp-ADPaS was still ago-
nist. Hence, the new pharmacological profile of the human 
P2Yi receptor was 2MeSADP > ADP with ATP, Sp-
ATPaS, aßMeATP, ßyMeATP, UTP and adenosine being 
ineffective (Fig. IB). In addition, 100 uM ATP induced a 
parallel right shift in dose-dependent calcium responses to 
ADP, while the inhibition by ATP could be overcome at 
high concentrations of ADP (Fig. 2A). Hence ATP was 
clearly a competitive antagonist of the receptor. Purified Sp-
ATPaS (10 uM) also inhibited 1 uM ADP-induced increases 
in [Ca2+]; in a competitive manner and whereas 1 mM 
ßyMeATP exhibited antagonistic effects, 1 mM aßMeATP 
was inactive (Fig. 2B; Table 1). The non-selective P2 receptors 
antagonists suramin (100 uM) and PPADS (10 uM) both 
inhibited calcium increase induced by 1 \iM ADP (Fig. 2B). 
2MeSATP and 2C1ATP, once purified, still appeared to be 
agonists but elicited a different calcium response, character-
ized by a lag time (15-20 s) followed by a gradual increase (40 
s) leading to a sustained calcium signal which returned pro-
gressively to basal levels (Fig. 3A). In order to assess the 
action of 2MeSATP and 2C1ATP on the P2Yi receptor, we 
examined their susceptibility to enzyme degradation. Classical 
methods of nucleotide analysis using perchloric acid for pro-
tein precipitation could not be employed for 2MeSATP and 
2C1ATP due to their instability at acidic pH. To circumvent 
this problem, we used a direct bioassay in which 100 uM 
purified 2MeSATP or 2C1ATP was incubated with mock-
transfected Jurkat cells (2x 106 cells) at 37°C under slow ag-
itation for 5 min. These cells were then centrifuged and an 
aliquot of the supernatant was added to fura-2-loaded P2Yi-
transfected Jurkat cells. The resulting 2MeSATP or 2C1ATP 
calcium signals were similar to that obtained after addition of 
non-purified 2MeSATP or 2C1ATP (Fig. 3B). Equivalent re-
sults were observed when 2MeSATP and 2C1ATP were incu-
bated with the ATP diphosphohydrolase apyrase (EC 3.6.1.5), 
which converted 2MeSATP to 2MeSADP and 2C1ATP to 
2C1ADP (data not shown). Control supernatants from 
mock-transfected Jurkat cells incubated with buffer alone 
had no effect. 
In terms of [Ca2+]; responses, the pharmacological proper-
ties of the P2Yi receptor are strikingly similar to those of the 
ADP receptor present on human platelets [23] (Table 1). Thus, 
we employed PCR amplification to look for the presence of 
P2Yi receptor mRNA in megakaryoblastic cell lines (MEG-
01, Dami, CHRF-288, HEL and K562) and in human plate-
lets. As shown in Fig. 4, a 1198 bp amplification product 
corresponding to the entire coding sequence of 'PlYi was 
Table 1 
Comparison of the pharmacological characteristics, in terms of 
[Ca2+]i movements, both of the human P2Yi receptor heterolog-
ously expressed and of the human P2T receptor 
'P2T' receptor" P2Yi receptor 
Agonists 
2MeSADP 
ADP 
ADPaS 
ADPßS 
Antagonists 
Sp-ATPaS 
ATP 
ßyMeATP 
2C1ATP 
2MeSATP 
Suramin 
PPADS 
Without effect 
aßMeATP 
UTP 
Adenosine 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
(full) EC5 0=41 nM 
(full) EC50 = 800 nM 
(partial) 
(partial) 
(competitive) 
(competitive) 
(competitive) 
(competitive) 
(non-competitive) 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
V 
? 
+ 
+ 
+ 
+ 
+ 
(full)EC50 = 49 nM 
(full) EC50 = 204 nM 
(nd) 
(nd) 
(competitive) 
(competitive) 
(competitive) 
"According to [23]. 
nd: not determined; ?: inconclusive (delayed effect due to enzymatic 
degradation and chemical instability in solution). 
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detected in all the megakaryoblastic cell lines tested and in 
platelets. U373 cells and native Jurkat cells were found to 
be negative for P2Yi mRNA (data not shown). When this 
amplification product was purified and sequenced, its nucleic 
acid sequence showed 100% identity with the human P2Yi 
receptor. 
4. Discussion 
Previously, we reported the cloning of a human P2Yi re-
ceptor highly homologous to the chick, rodent and bovine 
P2Yi receptor [19]. In the present paper, we report the phar-
macological characteristics of another cloned P2Yi receptor, 
differing from the first by the presence of an additional serine 
residue in transmembrane domain 3. This serine residue is 
present in all the P2Y receptors sequenced so far and is highly 
conserved in most of the G-protein-coupled receptors. 
Whether the absence of this serine in our first clone represents 
a point mutation or a polymorphism is not clear at the mo-
ment. Whatever it is, we only got responsive cellular clones 
expressing the serine residue-containing receptor. The phar-
ö 
O 
S 
Time (s) 
B 
ö 
o 
o 
E 
Time (s) 
Fig. 3. Variations in fluorescence ratio in fura-2-loaded Jurkat cells 
expressing the human P2Y! receptor induced by purified 2MeSATP 
(10 uM) (1) and by non-purified 2MeSATP (10 uM) (2) A: Demon-
stration of 2MeSATP catabolism at the surface of human Jurkat 
cells. Comparison between purified 2MeSATP (10 uM) (1) or puri-
fied 2MeSATP (10 U.M) previously incubated for 5 min with mock-
transfected Jurkat cells (2) B: Arrows indicate the time of nucleo-
tide addition. 
Fig. 4. Detection of P2Y! mRNA by PCR amplification. A 1198 bp 
amplification product was analyzed on 1% agarose gel and visual-
ized by ethidium bromide staining (arrow). Lane 1, molecular 
weight marker VI (Boehringer); lane 2, MEG-01 cells; lane 3, 
DAMI cells; lane 4, K562 cells; lane 5, CHRF-288 cells; lane 6, 
HEL cells; lane 7, human platelets; lane 8, control reaction in the 
absence of cDNA template. 
macological profile first obtained was consistent with obser-
vations for the other heterologously expressed P2Yi receptor 
[4,16-18,20,21]. We found 2MeSATP, 2C1ATP and 2Me-
SADP to be more potent agonists than ADP, Sp-ATPocS 
and ATP being partial agonists. ocßMeATP and ßyMeATP 
were without agonistic effect. A partial agonistic effect of 
ATP has been observed for the bovine P2Yi receptor [18] 
and also for the chick P2Yi receptor for which several related 
ATP derivatives were partial agonists [24,25]. This partial ag-
onistic feature was remarkable since P2Yx receptors have long 
been described as adenine nucleotide triphosphate receptors. 
Since a partial agonistic action could arise from degrada-
tion of the nucleotide triphosphates, ATP and ATP analogues 
were checked for purity by HPLC and repurified when neces-
sary. Purification changed the pharmacological profile of the 
human P2Yi receptor. In this report we show that contrary to 
common knowledge, the human P2Yi receptor is a nucleotide 
diphosphate receptor for which nucleotide triphosphates can-
not be considered to be agonists. 2MeSADP is a more potent 
agonist than ADP, while ATP, Sp-ATPaS and ßyMeATP are 
competitive antagonists of the ADP-induced [Ca2+]i rise, 
ocßMeATP, adenosine and UTP being without effect. This 
discrepancy with previous studies is mainly due to the fact 
that commercial nucleotide preparations are not pure. Such 
preparations require further purification, as even small 
amounts of contaminant products can lead to an artefactual 
agonistic effect. Erroneous pharmacological profiles have al-
ready been observed for other P2 receptors, due to contami-
nation of nucleotide stock solutions and enzymatic metaboli-
zation [26,27]. Although purified, 2MeSATP and 2C1ATP still 
elicited a calcium signal. This signal was delayed probably due 
to the metabolization by ectoenzymes and to the relatively 
high chemical instability of these compounds in solution, 
although we cannot absolutely rule out the possibility that 
2MeSATP and 2C1ATP exert a real agonistic effect. Therefore 
this is also a possible explanation why ATP was found to be a 
full agonist when IP3 production was measured at 10 min 
stimulation [20]. It would be useful to have selective inhibitors 
of the various ectonucleotidases in order to distinguish be-
tween these different phenomena. 
Since we show that the human P2Yi receptor is in fact an 
ADP receptor for which ATP is an antagonist, the question 
arises as to whether the P2Yi receptor might be the ADP 
receptor expressed by platelets and commonly referred to as 
the P2T receptor. The P2T receptor is indeed activated by 
ADP, 2-substituted ADP analogues being the most potent 
30 C. Leon et al.lFEBS Letters 403 (1997) 26-30 
agonists [14]. ATP, Sp-ATPaS, ßyMeATP and 2C1ATP are 
competitive antagonists, whereas 2MeSATP is a non-compet-
itive antagonist and aßMeATP and adenosine are inactive 
[11,14,23]. The pharmacological profile determined in the 
present work for the human P2Yi receptor is in agreement 
with that of the P2T receptor (Table 1). In view of these 
results, it appears that the human P2Yi and P2T receptors 
display very similar if not identical pharmacological proper-
ties, although on account of the delayed action of 2MeSATP 
and 2C1ATP, we were unable to demonstrate an antagonistic 
effect of these 2-substituted nucleotides at the P2Yi receptor. 
Moreover, the P2Yi mRNA was found to be present both in 
human platelets and in megakaryoblastic cells. The cloning of 
human P2Y! receptor from HEL cells was also reported dur-
ing the course of our study [28]. 
Pharmacological studies and the evidence for the presence 
of P2Yi mRNA in platelets and megakaryoblastic cells 
strongly support that the P2Yi receptor is the platelet P2T 
receptor. In platelets, ADP induces [Ca2+]j increase and in-
hibits adenylate cyclase [10,11] whereas most P2Yx receptors 
described to date are coupled to phospholipase C. However, 
transduction mechanisms may vary according to the cell type 
expressing the receptor and some P2Yi receptors have been 
shown to be coupled to adenylate cyclase in some native cells, 
for example in the case of the rat P2Yi receptor [24,29]. When 
endogenously expressed by BIO cells, a brain capillary endo-
thelial cell line, this receptor is indeed coupled to adenylate 
cyclase, and likewise in the rat glioma cell line C6-2B, whereas 
in cultured brain astrocytes it is associated with inositol phos-
phate production [24]. However, whether the P2Yi receptor is 
the receptor involved in platelet aggregation remains to be 
demonstrated. It would be of interest to check whether so-
called selective P2T antagonists such as ARL66096 and 
ARL67085 (previously known as FPL) [30] have an effect 
on this receptor. Unfortunately, these compounds are not 
commercially available. ARL66096 has been shown to antag-
onize ADP-induced platelet aggregation with a pA^ of 8.66 
while it inhibited 2MeSATP-induced guinea pig aorta relaxa-
tion with a pÄß of 4.71 [31]. This discrepancy in potency 
might be due firstly to the fact that aorta contains more 
than one subtype of P2 receptors [1]. Secondly, the antago-
nistic potency of ARL66096 has not been determined toward 
2MeSADP which is 20-fold more potent than ADP as an 
agonist of platelet aggregation. 
In summary, we have cloned and stably expressed the hu-
man P2Yi receptor and report that: (i) this receptor exhibits 
the pharmacological profile of the human platelet P2T recep-
tor and (ii) it is expressed by both megakaryoblastic cell lines 
and human platelets. These data strongly suggest that the 
P2Yi receptor may be the elusive P2T receptor. 
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